文献速递淋巴瘤

在高危侵袭性B细胞淋巴瘤患者中加倍利妥昔单抗——DENSE-R-MegaCHOEP试验结果

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
PubMed 文献 · Br J Haematol · 2018-12-05

DENSE-R-MegaCHOEP试验在77例年龄调整国际预后指数2-3分的年轻高危弥漫大B细胞淋巴瘤患者中,将利妥昔单抗输注次数加倍至12次并联合8周期CHOEP-14,回顾性对比标准R-MegaCHOEP试验中6次利妥昔单抗联合8周期CHOEP-14的患者。加倍利妥昔单抗未改善治疗结局,但仅接受6次利妥昔单抗联合CHOEP的年轻高危患者总生存和无进展生存仍优异。

要点

  • 12次利妥昔单抗联合CHOEP-14与6次利妥昔单抗联合CHOEP-14相比,2年EFS、PFS和OS均无差异。
  • 2年OS为82%(95%CI 73%-92%),2年EFS为69%(95%CI 59%-80%),2年PFS为76%(95%CI 66%-6%)。
  • 仅接受6次利妥昔单抗联合CHOEP的年轻高危患者OS和PFS仍优异,并在独立队列中确认。

核心结论

  • 在CHOEP方案基础上将利妥昔单抗输注次数加倍并未改善年轻高危DLBCL患者的治疗结局。
  • 仅接受6次利妥昔单抗联合CHOEP的年轻高危患者OS和PFS仍优异,并在独立队列中得到确认。

研究设计与样本

  • 77例年龄18-60岁、年龄调整国际预后指数2-3分的DLBCL患者接受12次利妥昔单抗(375 mg/m2)联合8周期CHOEP-14。
  • 结果回顾性对比随机R-MegaCHOEP试验标准组中接受6次利妥昔单抗联合8周期CHOEP-14的患者。

主要发现

  • 2年OS为82%(95%CI 73%-92%);2年EFS为69%(95%CI 59%-80%);2年PFS为76%(95%CI 66%-6%)。
  • 12次与6次利妥昔单抗相比,2年EFS为69% vs 71%,P=0.766。
  • 12次与6次利妥昔单抗相比,2年PFS为76% vs 75%,P=0.871。
  • 12次与6次利妥昔单抗相比,2年OS为82% vs 85%,P=0.843。

关键数值与推荐

  • 利妥昔单抗375 mg/m2于第0、1、4、8、15、22、29、43、57、71、85和99天给药,共12次,联合8周期CHOEP-14。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To further improve outcome in young high-risk patients with diffuse large B-cell lymphoma (DLBCL) the number of rituximab (R) infusions was doubled in combination with standard CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone) chemotherapy. Seventy-seven patients (aged 18-60 years) with an age-adjusted International Prognostic Index of 2-3 received 12 × R (375 mg/m2 ) on days 0, 1, 4, 8, 15, 22, 29, 43, 57, 71, 85 and 99 together with eight cycles of CHOEP-14. Results were retrospectively compared to those of patients receiving 6 × R and 8 × CHOEP-14 in the standard arm of the randomized R-MegaCHOEP trial. Two-year overall survival (OS) was 82% [95% confidence interval (CI) 73%-92%]; 2-year event-free (EFS) and progression-free survival (PFS) was 69% (95% CI 59-80%) and 76% (95% CI 66%--6%), respectively. Comparing 12 to six doses of R revealed no differences (univariate/multivariate) in EFS (at 2 years: 69% vs. 71%), PFS (76% vs. 75%) and OS (82% vs. 85%), with P = 0·766, P = 0·871 and P = 0·843, respectively. Doubling the number of R infusions concomitant to CHOEP did not improve treatment outcomes. Nonetheless, OS and PFS of young high-risk patients who received only six infusions of R combined with CHOEP remain excellent and were confirmed in an independent cohort of patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Friedrichs B, Nickelsen M, Ziepert M, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Br J Haematol. 2018. PMID: 30520013. doi:10.1111/bjh.15710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。